sur ADOCIA (EPA:ADOC)
Adocia Reports 2025 Financial Results and Strategic Developments
Adocia, a biopharmaceutical company, announced its 2025 financial results. The cash position was €17.2 million as of December 31, 2025. Key developments include the completion of BioChaperone® Lispro's Phase 3 trials in China by partner Tonghua Dongbao, achieving positive results. The company continued collaboration for BioChaperone® and filed a patent for the AdoXLong™ platform, showing promising preclinical results. A clinical trial application is planned for the AdoShell® platform in Q3 2026.
In 2025, Adocia faced a net loss of €16.6 million, up from a €9.3 million loss in 2024, attributed to lower revenue. Revenue was €1.5 million compared to €9.3 million in the previous year. Post-period, a loan agreement with Vester Finance was secured, extending the cash runway to Q2 2027. Governance changes included appointing Stéphane Boissel as Chairman and Jacky Vonderscher as a Director.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ADOCIA